Needham & Company LLC Reaffirms "Buy" Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "buy" rating restated by analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They presently have a $9.00 target price on the stock. Needham & Company LLC's price target points to a potential upside of 105.01% from the stock's current price.

Separately, Truist Financial lifted their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $8.70.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock traded up $0.32 during midday trading on Friday, reaching $4.39. 2,033,136 shares of the company were exchanged, compared to its average volume of 1,690,866. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -3.69 and a beta of 2.03. The firm's 50-day simple moving average is $5.01 and its 200-day simple moving average is $5.32. Autolus Therapeutics has a 1 year low of $2.01 and a 1 year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). On average, analysts forecast that Autolus Therapeutics will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 3rd quarter worth $679,000. China Universal Asset Management Co. Ltd. acquired a new stake in Autolus Therapeutics during the fourth quarter worth about $105,000. Exchange Traded Concepts LLC raised its holdings in shares of Autolus Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company's stock worth $315,000 after purchasing an additional 12,387 shares during the period. Lynx1 Capital Management LP acquired a new position in shares of Autolus Therapeutics in the 3rd quarter valued at about $3,176,000. Finally, Rathbones Group PLC purchased a new stake in shares of Autolus Therapeutics during the 3rd quarter worth about $171,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.